Gliclazide Tablets
Function and Efficacy
This product is a second-generation sulfonylurea hypoglycemic drug with a strong effect. Its mechanism is to selectively act on pancreatic islet cells to promote insulin secretion and increase insulin release after eating glucose, so that the production and output of glycogen are inhibited. Animal experiments and clinical use have proven that this product can reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.
Ingredients
Gliclazide.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| GliclazideIngredients |
The second-generation sulfonylurea hypoglycemic drug selectively acts on pancreatic beta cells, promoting insulin secretion and increasing insulin release after ingesting glucose, thereby inhibiting liver glucose production and output; it reduces platelet aggregation and adhesion, and helps prevent and treat diabetic microangiopathy. More |
21187-98-4 | 22 |
Appearance
This product is white tablets.
Indication
Non-insulin-dependent diabetes mellitus.
Usage and Dosage
It should be taken under the guidance of a physician, with an initial oral dose of 40-80 mg, 1-2 times a day, and then adjusted to 80-240 mg a day, divided into 2-3 doses, based on blood and urine sugar levels. After blood and urine sugar levels are controlled, the daily maintenance dose can be changed. Elderly patients should reduce the dose as appropriate.
Adverse Reactions
Occasionally, there may be mild nausea, vomiting, upper abdominal pain, constipation, diarrhea, erythema, urticaria, thrombocytopenia, granulocytopenia, anemia, etc. Most of them disappear after stopping the drug.
Precautions
1. Patients with impaired liver and kidney function are contraindicated. 2. Patients allergic to sulfonylureas are contraindicated.
Special Population Medication
Precautions for children: Not clear yet. Precautions for pregnancy and lactation: Animal experiments and clinical observations have shown that sulfonylurea hypoglycemic drugs can cause teratogenesis and are excreted through breast milk, so pregnant women and nursing mothers should not use them. Precautions for the elderly: The dosage should be appropriately reduced.
Drug Interactions
When used in combination with non-steroidal anti-inflammatory drugs (especially salicylates), sulfonamide antibiotics, coumarin anticoagulants, monoamine oxidase inhibitors, β-receptor blockers, benzodiazepines, tetracycline, chloramphenicol, dicyclohexine, clofibrate, ethanol and other drugs, the dosage should be reduced to avoid hypoglycemia.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
80mg
Validity Period
36 months
Manufacturer
Sichuan Meidakang Pharmaceutical Co., Ltd.
-
Founded in:
2000-08-22 -
Address:
Jinhe East Road, Shifang City, Sichuan Province -
Tax NO.:
9151060062089018XJ -
Registered Funds:
116 million yuan -
Website:
-
Email: